Dyslipidemia

A primary investigator-led discussion will tap into how invasive procedures have become more embraced in US cardiology.

Results of the phase 3 trial show that inclisiran reduced LDL cholesterol in patients with atherosclerotic cardiovascular disease.

Severe vitamin D deficiency in people with diabetes treated with dual antiplatelet therapy (DAPT) after an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) is associated with high residual platelet reactivity in patients taking the adenosine-diphosphate (ADP) antagonists ticagrelor or prasugrel, according to an exploratory study epublished on June 7 by Vascular Pharmacology.

The advent of newer antiplatelet agents and oral anticoagulants has allowed new regimens for secondary prevention of coronary artery disease. When combination therapy is needed, the bleeding risk is particularly pronounced, and the benefits and risks must be balanced for individual patients.

While results of COMPASS proved the efficacy of combination rivaroxban-plus-aspirin, it may not be the best treatment for every patient suffering from coronary or peripheral artery disease.

A team of investigators review global HCV infection rates in an attempt to quantify HCV-associated cardiovascular disease.

After showing a significant impact on reduction of cardiovascular events, a slew of subgroup analyses were performed examining use of icosapent ethyl using data derived from REDUCE-IT.

The investigative monoclonal antibody from Regeneron shows significant benefit for patients with the rare, severe homozygous familial hypercholesterolemia.

Trial investigator Deepak Bhatt, MD, MPH, discusses how use of rivaroxaban in a clinical setting has changed as a result of the COMPASS trial.

Lead investigator of REDUCE-IT trials discusses the impact of trial results and what that means for EPA-based treatments going forward.

Use of rivaroxaban (Xarelto) plus aspirin was found to reduce cardiovascular and major limb events in a secondary analysis of the COMPASS trial.

In a recent study, investigators from Johns Hopkins found that risks of peripheral artery disease remains elevated for 30 years after smoking cessation.

A recent study has found that the cost and accessibility of PCSK9 inhibitors has created problems for patients seeking an effective treatment for their hypercholesterolemia.

From vaping to air pollution, Deepak Bhatt, MD, shares his thoughts on the greatest threats to cardiovascular health.

A new study links high levels of high‐sensitivity cardiac troponin T and N‐terminal pro‐B‐type natriuretic peptide to an increase in fall risk for geriatric adults.

A recent analysis of the IMPROVE-IT results found that simvastatin-ezetimibe was associated with greater reductions in LDL-C and lower rates of MI, stroke and CVD than simvastatin monotherapy.

Study from investigators in London found that high iron levels were associated with a lower risk of high cholesterol levels and reductions in atherosclerosis, but these same high levels were also associated with increased risk of stroke.

Professor of medicine at Harvard Medical School discusses how much progress has been made in the fight against cardiovascular disease.

Over time, clinicians have come to understand the most optimal use of the limited technological resources they have.

How the institution has become involved in regional health education efforts, and national efforts to establish proper care protocol.

Why limited educational resources and a diverse population has made the region an area burdened by heart disease.